Abdulaziz Alsharif

Publication Activity (10 Years)

Years Active: 2023-2023
Publications (10 Years): 4

Top Topics

Men Who Have Sex With Men

Multidrug Resistant

Cystic Fibrosis

Acinetobacter Baumannii

Top Venues

Medicina (Kaunas, Lithuania)

Antioxidants (Basel, Switzerland)

This page only lists publications with an associated author ORCID identifier.

Publications

Tafadzwa Dzinamarira, Mazen M Almehmadi, Ahad Amer Alsaiari, Mamdouh Allahyani, Abdulelah Aljuaid, Abdulaziz Alsharif, Abida Khan, Mehnaz Kamal, Ali A Rabaan, Amal H Alfaraj, Bashayer M AlShehail, Nouf E Alotaibi, Shams M AlShehail, Mohd Imran
Highlights on the Development, Related Patents, and Prospects of Lenacapavir: The First-in-Class HIV-1 Capsid Inhibitor for the Treatment of Multi-Drug-Resistant HIV-1 Infection. Medicina (Kaunas, Lithuania) 59 (6) (2023)
Shabnam Shabir, Amit Sehgal, Joydeep Dutta, Inderpal Devgon, Sandeep Kumar Singh, Walaa F Alsanie, Abdulhakeem S Alamri, Majid Alhomrani, Abdulaziz Alsharif, Mohammed Abubaker Mohammed Basalamah, Hani Faidah, Farkad Bantun, Abdullah Ali Saati, Emanuel Vamanu, Mahendra P Singh
Therapeutic Potential of Green-Engineered ZnO Nanoparticles on Rotenone-Exposed D. melanogaster (Oregon R + ): Unveiling Ameliorated Biochemical, Cellular, and Behavioral Parameters. Antioxidants (Basel, Switzerland) 12 (9) (2023)
Tafadzwa Dzinamarira, Mazen M Almehmadi, Ahad Amer Alsaiari, Mamdouh Allahyani, Abdulelah Aljuaid, Abdulaziz Alsharif, Abida Khan, Mehnaz Kamal, Ali A Rabaan, Amal H Alfaraj, Bashayer M AlShehail, Nouf E Alotaibi, Shams M AlShehail, Mohd Imran
Highlights on the Development, Related Patents, and Prospects of Lenacapavir: The First-in-Class HIV-1 Capsid Inhibitor for the Treatment of Multi-Drug-Resistant HIV-1 Infection. Medicina (Kaunas, Lithuania) 59 (6) (2023)
Tafadzwa Dzinamarira, Mazen M Almehmadi, Ahad Amer Alsaiari, Mamdouh Allahyani, Abdulelah Aljuaid, Abdulaziz Alsharif, Abida Khan, Mehnaz Kamal, Ali A Rabaan, Amal H Alfaraj, Bashayer M AlShehail, Nouf E Alotaibi, Shams M AlShehail, Mohd Imran
Highlights on the Development, Related Patents, and Prospects of Lenacapavir: The First-in-Class HIV-1 Capsid Inhibitor for the Treatment of Multi-Drug-Resistant HIV-1 Infection. Medicina (Kaunas, Lithuania) 59 (6) (2023)